AMGN

Amgen (NASDAQ:AMGN) today announced that the Japanese Ministry of Health, Labour and Welfare has granted marketing approval for Aimovig® (erenumab) for the suppression of onset of migraine attacks in adults. Aimovig is the first and only approved treatment in Japan to block the calcitonin gene-related peptide receptor (CGRP-R), which is believed to play a critical role in migraine.3 This is also the first independent submission and approval for Amgen K.K., a wholly owned affiliate of Amgen Inc.

Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips or bumps on the charts usually don’t make them change their opinion towards a company. This time it may be different. The coronavirus pandemic destroyed the high correlations among major industries and asset classes. We are […]

Scientists from deCODE genetics have developed a predictor based on protein measurements in blood samples that predicts the time to all-cause death better than traditional risk factors.

Dividend stocks can be a great source of passive income, and fortunately, there is no shortage of dividend-paying companies in the stock market. After all, many companies slash, or outright suspend, their dividends once the economy stops working in their favor. If you are looking for dividend stocks that can pay you for the rest of your life, rest assured: They exist.

Amgen (NASDAQ:AMGN) and Otezla® (apremilast) have partnered with Allan Avendaño, makeup artist to Hollywood A-listers, for the INSIDE LOOK campaign to share his journey living with plaque psoriasis and the difficulties of being in his demanding role and dealing with a chronic skin condition. No stranger to the fast pace and demands of the entertainment industry, Avendaño knows that the show must go on no matter what obstacles, or plaques, arise—something many people living with plaque psoriasis

Does the June share price for Amgen Inc. ( NASDAQ:AMGN ) reflect what it's really worth? Today, we will estimate the...

Julie Hyman and Anjalee Khemlani breakdown what the FDA’s approval of Biogen’s Alzheimer’s drug will mean for the pharmaceutical industry as Biogen experienced a surge in shares and releases the cost of the treatment.

View more earnings on AMGNSee more from BenzingaClick here for options trades from BenzingaAmgen's Stomach Cancer Drug Acquired in Five Prime Buyout Extends Patients' Lives, Mid-Stage Study ShowsAmgen, Kyowa Kirin Ink .25B Deal for Developing KHK4083 In Skin Disorders© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 42nd Annual Global Healthcare Conference at 4:40 p.m. ET on Wednesday, June 9, 2021. David M. Reese, M.D., executive vice president of Research and Development and Peter H. Griffith, executive vice president and chief financial officer at Amgen will present at the conference. Live audio of the conference call will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public

Amgen (NASDAQ: AMGN) today presented data on overall survival, a secondary endpoint, from the Phase 2 results of the CodeBreaK 100 clinical study for LUMAKRASTM (sotorasib) in previously treated patients with non-small cell lung cancer (NSCLC) during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. These data were also simultaneously published in the New England Journal of Medicine (NEJM). The publication includes mature overall survival and duration of response data, and re

Amgen Inc (NASDAQ: AMGN) has announced updated results for investigational bemarituzumab combined with chemotherapy from the Phase 2 FIGHT trial in patients with FGFR2b-positive, HER2-negative frontline advanced gastric or gastroesophageal junction cancers (GEJ). Bemarituzumab is the crown jewel of the Five Prime Therapeutics $1.9 billion buyout, which showed the treatment helped patients with advanced stomach cancer live longer. Patients taking the treatment and a chemotherapy combination lived

Amgen (NASDAQ:AMGN) today announced updated results for investigational bemarituzumab in combination with chemotherapy from the Phase 2 FIGHT trial. The trial evaluated bemarituzumab plus chemotherapy (mFOLFOX6) versus chemotherapy alone in patients with FGFR2b-positive, HER2-negative frontline advanced gastric or gastroesophageal junction cancers (GEJ). New data includes median overall survival (OS), a secondary endpoint that was reached with longer follow-up, as well as additional analyses of

Biotechnology stocks are famous for dramatic price movements but smart investors have been eager to scoop up shares of Amgen (NASDAQ: AMGN) for a different reason. Despite its size, Amgen can move quickly where it matters most. On May 28, 2021, the FDA granted a highly accelerated approval to a new lung cancer therapy in record time.

In this article we are going to list the 15 most valuable pharmaceutical companies in the world. Click to skip ahead and jump to the 5 most valuable pharmaceutical companies in the world. There is no denying the impact that the global pharma industry has had in the world, and probably been responsible for the […]

Amgen (NASDAQ: AMGN) will host a webcast call for the investment community in conjunction with the American Society of Clinical Oncology (ASCO) Annual Meeting at 4:00 p.m. ET on Friday, June 4, 2021. David M. Reese, M.D., executive vice president of Research and Development at Amgen, along with members of Amgen's clinical development team, will discuss clinical data being presented on the Company's recently FDA-approved KRASG12C inhibitor LUMAKRAS™ (sotorasib), anti-FGFR2b antibody bemarituzumab

QIAGEN's (QGEN) therascreen KRAS kit to be used with LUMAKRAS is claimed to provide clinicians with a wide range of biomarker testing options, critical to patients with NSCLC.

Amgen (AMGN) inks an agreement with Kyowa Kirin Co. to develop and commercialize the latter's KHK4083, which is being developed for the treatment of atopic dermatitis.

ArcelorMittal and Devon Energy rallied, Boeing topped the Dow Jones today as stocks posted a strong start to the month of June.

Amgen Inc (NASDAQ: AMGN) and Kyowa Kirin Co Ltd (OTC: KYKOF) have agreed to jointly develop and commercialize KHK4083, Kyowa Kirin's Phase 3-ready anti-OX40 fully human monoclonal antibody in development for atopic dermatitis, with potential in other autoimmune diseases. In February, Kyowa Kirin announced positive results from a Phase 2 study of KHK4083 in patients with moderate-to-severe atopic dermatitis. In exchange for an upfront of $400 million and milestones worth up to $850 million, Amgen

Amgen (NASDAQ: AMGN) and Kyowa Kirin Co., Ltd. (TSE: 4151) today announced an agreement to jointly develop and commercialize KHK4083, which is Kyowa Kirin's potential first-in-class, Phase 3-ready anti-OX40 fully human monoclonal antibody in development for the treatment of atopic dermatitis, with potential in other autoimmune diseases. In February, Kyowa Kirin announced positive results from a Phase 2 study of KHK4083 in patients with moderate-to-severe atopic dermatitis, which affects nearly 30 million people in major global markets1.